Cold type haemolytic anaemia – Diagnostics – Overview of Information and Clinical Research

Diagnosing cold type haemolytic anaemia requires a combination of clinical observation, blood tests, and specialized laboratory studies to confirm the presence of cold-reactive antibodies and assess the severity of red blood cell destruction.

Introduction: Who Should Undergo Diagnostics

People who experience symptoms of anaemia (a condition where you don’t have enough red blood cells) combined with unusual reactions to cold temperatures should consider seeking medical evaluation. If you notice that your fingers, toes, or ears turn blue or purple when exposed to cold, or if you feel unusually tired, weak, or dizzy especially during colder months, it’s important to consult your healthcare provider.^[1]

These symptoms can indicate cold type haemolytic anaemia, where your immune system mistakenly attacks your red blood cells when you’re exposed to cold temperatures. The condition is rare, affecting approximately one in a million people each year, but early diagnosis is crucial because it allows your healthcare team to start appropriate management and help you avoid complications.^[1]

You should seek diagnostic testing promptly if you notice dark brown-coloured urine, yellowing of your skin or the whites of your eyes, rapid heartbeat, shortness of breath, or extreme fatigue that interferes with daily activities. These signs suggest that red blood cells are being destroyed faster than your body can replace them, which requires medical attention.^[1]

People with existing autoimmune conditions, certain infections (like infectious mononucleosis or mycoplasma pneumonia), or blood cancers such as lymphoma should also be evaluated for cold type haemolytic anaemia if they develop anaemia symptoms, as these conditions can trigger secondary forms of the disease.^[2]

⚠️ Important

Symptoms of cold type haemolytic anaemia may develop very slowly over several years, making it easy to overlook them initially. Some people live with mild cases for years before receiving a diagnosis. However, in severe cases, the condition can lead to life-threatening heart problems, so don’t delay seeking medical attention if you experience concerning symptoms.

Classic Diagnostic Methods

The diagnostic process for cold type haemolytic anaemia involves multiple steps and various tests to confirm the diagnosis and distinguish it from other forms of anaemia. Your healthcare provider will start with a thorough medical history and physical examination, asking about your symptoms, when they occur, and whether cold exposure triggers or worsens them.^[4]

Complete Blood Count and Peripheral Smear

The first laboratory test is typically a complete blood count (CBC), which measures the number of different types of blood cells in your body. In cold type haemolytic anaemia, this test will show a low red blood cell count, indicating anaemia. Your haemoglobin level (the protein in red blood cells that carries oxygen) will also be reduced.^[3]

A peripheral blood smear is particularly revealing for this condition. Laboratory technicians examine your blood under a microscope and look for characteristic clumps of red blood cells. These clumps form because the cold-reactive antibodies cause red blood cells to stick together (agglutinate) at cooler temperatures. The presence of these clumps is a strong indicator of cold type haemolytic anaemia.^[3]

Direct Antiglobulin Test

The direct antiglobulin test (DAT), also called the Coombs test, is essential for diagnosing autoimmune haemolytic anaemias. This test detects antibodies or complement proteins (part of the immune system) that are attached to the surface of your red blood cells. In cold type haemolytic anaemia, the test typically shows a positive result for C3d (a complement protein) and a negative result for immunoglobulin G (IgG).^[4]^[7]

This pattern helps distinguish cold type haemolytic anaemia from warm autoimmune haemolytic anaemia, where IgG antibodies are usually present. The test essentially confirms that your immune system is inappropriately targeting your own red blood cells.^[4]

Cold Agglutinin Titre Testing

A critical test for diagnosing cold type haemolytic anaemia is the cold agglutinin titre, which measures the amount of cold-reactive antibodies in your blood. The test is performed at 4 degrees Celsius (about 39 degrees Fahrenheit) to see how strongly the antibodies react at cold temperatures. A titre of 64 or higher at this temperature is considered significant, while titres of 1024 or higher strongly suggest cold agglutinin disease.^[4]^[7]

The thermal amplitude of these antibodies is also important. This refers to the highest temperature at which the antibodies can still bind to red blood cells. The severity of symptoms often depends on how close this temperature is to normal body temperature. If antibodies react at temperatures closer to 37 degrees Celsius (normal body temperature), you’re more likely to experience severe symptoms.^[4]

Reticulocyte Count

Your healthcare provider will measure your reticulocyte count, which indicates how quickly your bone marrow is producing new red blood cells. Reticulocytes are immature red blood cells. In haemolytic anaemia, the reticulocyte count is typically elevated because your bone marrow is working overtime to replace the red blood cells being destroyed. An elevated absolute reticulocyte count confirms that red blood cell destruction (haemolysis) is occurring.^[4]^[7]

Additional Blood Tests

Several other blood tests help confirm haemolysis and assess its severity. Lactate dehydrogenase (LDH) is an enzyme released when cells are damaged. Elevated LDH levels indicate that red blood cells are breaking down. Your healthcare provider will also check your haptoglobin level, a protein that binds free haemoglobin in the blood. When red blood cells are destroyed, haptoglobin levels drop because the protein gets used up binding to released haemoglobin. Low or undetectable haptoglobin is a hallmark of haemolytic anaemia.^[4]^[7]

Bilirubin testing is also important. When red blood cells break down, they release a yellowish substance called bilirubin. Elevated unconjugated bilirubin levels indicate ongoing haemolysis and explain symptoms of jaundice (yellowing of the skin and eyes). Your urine may also be tested for haemoglobin and bilirubin, which can cause dark-coloured urine.^[1]^[4]

Complement Levels

Measuring levels of complement proteins C3 and C4 in your blood helps understand how the immune system is contributing to red blood cell destruction. In cold type haemolytic anaemia, complement levels are often depleted (undetectable or very low) because these proteins are being consumed in the process of attacking red blood cells.^[4]^[7]

Protein Studies

Serum protein electrophoresis is performed to look for abnormal proteins in the blood. In primary cold agglutinin disease, this test often reveals a monoclonal protein, typically immunoglobulin M kappa (IgMκ), indicating that a single clone of immune cells is producing the problematic antibody. This finding suggests an underlying lymphoproliferative disorder, even if cancer hasn’t been detected.^[4]^[7]

Immunoelectrophoresis or immunofixation may be used to further characterize the abnormal antibodies, confirming whether they are immunoglobulin M (IgM) type, which is present in 90% of cold type haemolytic anaemia cases. Rarely, the antibodies may involve immunoglobulin G, immunoglobulin A, or light chain restriction.^[3]

Bone Marrow Biopsy

In some cases, particularly when trying to determine if there’s an underlying blood cancer or lymphoproliferative disorder, your doctor may recommend a bone marrow biopsy. This procedure involves taking a small sample of bone marrow tissue, usually from your hip bone, to examine under a microscope. The biopsy can reveal nodular B-cell aggregates and lymphoplasmacytoid cells that are characteristic of cold agglutinin-associated lymphoproliferative bone marrow disease.^[4]^[7]

Flow cytometry may be performed on the bone marrow sample to analyse the types and proportions of immune cells present. An abnormal ratio of kappa to lambda positive B cells suggests a clonal disorder. Genetic testing on the bone marrow sample may look for specific mutations, such as MYD88 L265P, which can help distinguish between different types of lymphoproliferative disorders.^[7]

Infectious Disease Testing

Because certain infections can trigger secondary cold type haemolytic anaemia, your healthcare provider may order tests to check for underlying infections. These might include tests for mycoplasma pneumonia, Epstein-Barr virus (which causes infectious mononucleosis), cytomegalovirus, HIV, hepatitis C, and other viral, bacterial, or parasitic infections. Identifying and treating an underlying infection is crucial because infection-related cold type haemolytic anaemia often resolves once the infection is treated.^[2]^[3]

Blood Typing Considerations

Blood typing can be challenging in people with cold type haemolytic anaemia because the cold-reactive antibodies interfere with standard blood typing procedures. The antibodies can cause red blood cells to clump together at room temperature, making it difficult to accurately determine blood type. Special techniques, such as warming the blood sample to body temperature before testing, may be necessary to obtain accurate results.^[3]

Diagnostics for Clinical Trial Qualification

If you’re considering participation in a clinical trial for cold type haemolytic anaemia, you’ll undergo additional diagnostic testing to determine if you meet the specific criteria for enrolment. Clinical trials have strict inclusion and exclusion criteria to ensure patient safety and study validity.^[4]

Standard qualification testing typically includes confirmation of the diagnosis through a positive direct antiglobulin test showing C3d positivity and IgG negativity, along with elevated cold agglutinin titres measured at 4 degrees Celsius. Your haemoglobin level will be measured to confirm that you have clinically significant anaemia. Many trials require haemoglobin levels below certain thresholds, such as 10 g/dL or lower, to ensure enrolled patients have active disease.^[4]^[7]

Laboratory markers of haemolysis must be documented, including elevated lactate dehydrogenase, low or undetectable haptoglobin, elevated bilirubin (particularly unconjugated bilirubin), and increased reticulocyte count. These measurements demonstrate that red blood cell destruction is actively occurring and help establish a baseline against which treatment effectiveness can be measured.^[7]

Trials may require documentation of complement consumption, shown by low or undetectable levels of C3 and C4. Some studies specifically enrol patients with primary cold agglutinin disease, so you may need a bone marrow biopsy to confirm lymphoproliferative disease and exclude other causes of cold-reactive antibodies. Serum protein electrophoresis demonstrating monoclonal IgM is often required to confirm primary disease.^[4]^[7]

Trials testing complement inhibitors may require specific complement testing to ensure your immune system’s complement pathway is functioning and could respond to the intervention. Flow cytometry results showing an abnormal kappa to lambda B-cell ratio may be required to document clonal B-cell disease.^[7]

Before enrolment, you’ll typically undergo testing to rule out other conditions that could affect trial participation. This includes screening for active infections, other autoimmune diseases, and other forms of anaemia. Kidney and liver function tests are standard, as impaired organ function may exclude you from certain trials or require dose adjustments of study medications.^[4]

Some trials require documentation of previous treatments you’ve received and their effectiveness. You may need records showing that you’ve tried and either not responded to or could not tolerate standard therapies like rituximab. Trials of newer medications often enrol patients with refractory disease, meaning their condition hasn’t improved with conventional treatments.^[3]^[6]

Baseline quality of life assessments and symptom severity scores are often collected as part of trial qualification. You may be asked to complete questionnaires about your symptoms, particularly cold-related symptoms like acrocyanosis, fatigue levels, and how the disease affects your daily activities. These assessments help researchers measure whether experimental treatments improve not just laboratory values but also how you feel and function.^[5]

Throughout your participation in a clinical trial, the same diagnostic tests will be repeated at regular intervals to monitor your response to treatment and watch for any adverse effects. This ongoing monitoring ensures your safety and provides valuable data about the experimental treatment’s effectiveness.^[4]

Prognosis and Survival Rate

Prognosis

The outlook for people with cold type haemolytic anaemia varies considerably depending on whether the condition is primary or secondary, and how severe the symptoms are. Primary cold agglutinin disease is generally considered a benign disorder with prolonged survival, though it is typically a chronic, lifelong condition. Most people with primary disease can manage their condition successfully through lifestyle modifications like avoiding cold exposure and wearing appropriate protective clothing.^[6]^[14]

For many patients with mild disease, symptoms may develop so gradually over several years that the condition goes undiagnosed for a long time. These individuals often have minimal impact on their daily lives and don’t require aggressive treatment. However, the disease can cause spontaneous exacerbations (worsening episodes) and remissions, meaning symptoms may come and go unpredictably throughout life.^[1]^[6]

Secondary cold type haemolytic anaemia has a different prognosis depending on its cause. When the condition develops after an infection, particularly in children and young adults, it is usually temporary and mild. These acute post-infectious cases typically resolve spontaneously once the underlying infection is treated, and patients make a full recovery.^[3]^[4]

Secondary disease associated with lymphoma or other blood cancers tends to be chronic and requires ongoing treatment. In these cases, the prognosis depends largely on the underlying malignancy and how well it responds to treatment. Managing the associated cancer often helps control the haemolytic anaemia as well.^[3]

The severity of disease is highly dependent on the thermal binding range of the autoantibody. People whose antibodies react at temperatures closer to normal body temperature (higher thermal amplitude) generally experience more severe and frequent symptoms. Those with antibodies that only react at very cold temperatures may have minimal symptoms except during winter months or in cold environments.^[4]^[7]

While cold type haemolytic anaemia is highly manageable with appropriate care, it can be fatal if left untreated, particularly in severe cases. The condition increases the risk of developing blood clots, strokes, and heart problems. In emergency scenarios with severe haemolysis, the anaemia can lead to life-threatening heart failure or other complications. This emphasises the importance of prompt diagnosis and treatment.^[1]^[5]

With modern treatment options, including rituximab-based regimens and newer complement inhibitors, many patients achieve good symptom control and improved quality of life. Response to treatment varies, with approximately 50% of patients showing partial response to rituximab therapy, though complete responses are rare. Treatment responses can last from several months to several years before requiring additional therapy.^[6]

Survival rate

Specific survival statistics for cold type haemolytic anaemia are not well-established in the medical literature, as the condition is very rare and outcomes vary significantly based on whether the disease is primary or secondary, the severity of symptoms, and the presence of underlying conditions. However, primary cold agglutinin disease is generally described as a benign disorder compatible with prolonged survival when properly managed.^[6]^[14]

Most people with mild to moderate primary disease who follow appropriate cold avoidance measures and receive treatment when needed can expect a normal or near-normal lifespan. The main factors affecting survival are typically related complications such as severe anaemia leading to heart problems, blood clots, or stroke, rather than the haemolytic anaemia itself.^[5]

For secondary cold type haemolytic anaemia, survival rates depend primarily on the underlying cause. Patients with infection-related disease typically have excellent outcomes once the infection resolves. Those with underlying lymphoma or other malignancies have survival rates determined by the cancer rather than the haemolytic anaemia specifically.^[3]

#1 Clinical Trials Search in Europe